Morphic Holding, Inc.

For full-year 2020, Morphic reported a net loss of $45 million, or $1.47 per share, versus a net loss of $43.3 million, or $2.69 per share in 2019. Collaboration revenue was $44.9 million in 2020, compared with $17 million in 2019, and R&D expense was $73.6 million versus $53.7 million in 2019. As of December 31, 2020, cash, cash equivalents, and marketable securities were approximately $228.3 million, compared with $237 million a year earlier. Management said cash is sufficient to fund operations into 2023. On the clinical side, MORF-057’s SAD study showed no SAEs, no clinically significant lab abnormalities, no quantifiable α4β1 inhibition, and mean α4β7 receptor occupancy greater than 70% at 25 mg, greater than 85% at 50 mg, and greater than 95% at 100 mg, 150 mg, and 400 mg, measured 12 hours post-dose. Management said the PK data were consistent with modeling and support BID dosing; MAD and food-effect studies are ongoing, with Phase 2 planning underway after full Phase 1 data are available.

Praveen Tipirneni struck a highly enthusiastic tone, calling the MORF-057 data a major validation of Morphic’s long-held thesis around oral integrin inhibition in IBD. He said the results were “even beyond our greatest expectations,” emphasized that the company had solved the hardest problem it had been worrying about—predicting human PK—and said the data make Morphic more confident in a BID regimen, while also acknowledging the possibility of exploring QD or formulation improvements later. He repeatedly framed the program as a platform proof point for the broader MInT approach.

Marc Schegerin highlighted a strong year on both business development and cash discipline. He cited the AbbVie collaboration milestones, including the $20 million option exercise payment on top of the original $100 million upfront, and said 2020 collaboration revenue rose to $44.9 million from $17 million in 2019. He also noted a year-end cash balance of approximately $228.3 million, with about $9 million of net cash burn in 2020, and said that balance should fund operations into 2023. He added that R&D increased to $73.6 million from $53.7 million due to external development costs and higher headcount/compensation.

Analysts focused mostly on what the Phase 1 receptor-occupancy data imply for dosing, future MAD readouts, and the speed to Phase 2. Management said the MAD and food-effect studies are ongoing and will provide equilibrium RO, multiple-dose safety, and patient-by-patient detail used with KOL input to design the Phase 2 program, with more details to be announced after the full Phase 1 dataset is reported mid-year. On the dosing question, management said the goal was always BID dosing and that the data were strong enough to make them more confident in BID, while keeping QD and formulation ideas as possibilities rather than promises.